Alkermes appoints Craig Hopkinson to its medical team

Ireland-incorporated biotech firm Alkermes (Nasdaq: ALKS) has named Craig Hopkinson to the posts of chief medical officer, and senior vice president of clinical development and medical affairs.

Dr Hopkinson will be responsible for the advancement and implementation of the clinical development programs for Alkermes’ pipeline of drug candidates. He will serve on the executive management team of Alkermes and report to Elliot Ehrich, executive VP of R&D. Dr Ehrich will transition his role as CMO to Dr. Hopkinson and will focus on advancing the company’s product pipeline and pharmaceutical development strategy.

“We are pleased to welcome Craig, an industry veteran and proven leader, whose expertise will help shape Alkermes’ next stage of growth. His experience will be invaluable to our current global research and clinical development efforts in CNS diseases,” said Richard Pops, chief executive of Alkermes, adding: “As our portfolio of new medicines expands, we are responding by strengthening our capabilities in providing scientific and medical information on the value of our products.”